Neurologic and hematologic response to fludarabine treatment in IgM MGUS polyneuropathy.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 17159126.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We studied the efficacy of fludarabine in 16 patients with immunoglobulin M monoclonal gammopathy of unknown significance polyneuropathy in a prospective uncontrolled trial. The modified Rankin scale improved in 5/16 patients, all of whom had a demyelinating polyneuropathy. The motor conduction velocity improved by more than 10% in two or more nerves for four of five of these patients. Hematologic response in bone marrow occurred in three of five of these patients, whereas two of five already had small polyclonal B cell populations. There were no serious side effects.
Medical subject headings
- Immunoglobulin M
- Paraproteinemias
- Polyneuropathies
- Vidarabine